your treatment plan your insurance coverage your location the cost of the visit to a healthcare professional to receive Carvykti available financial assistance for Carvykti (see the “Financial and ...

ROCHESTER, N.Y. – Wilmot Cancer Institute is among a select few cancer centers in the U.S. offering Carvykti, a treatment for multiple myeloma, a cancer in white blood cells that’s considered ...

Carvykti is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy. The Food and Drug Administration (FDA) has approved Carvykti ...

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat ...

--Johnson& Johnson announced today positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating CARVYKTI ® compared to standard therapies of pomalidomide, ...

As with other drugs, Carvykti (ciltacabtagene autoleucel) can cause side effects, such as fever and digestive issues. If you are not able to tolerate side effects of Carvykti, talk with your doctor or ...

Carvykti (ciltacabtagene autoleucel) is a type of cancer immunotherapy known as chimeric antigen receptor (CAR) T-cell therapy, which works to help the body’s immune system find and attack cancer ...

Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from ...

Early Carvykti administration in RRMM patients leads to durable, treatment-free remissions, with over 80% remaining progression-free at 30 months. Carvykti was FDA-approved for RRMM after four prior ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Promising first-in-human results from allogeneic CAR-T candidate LUCAR-G39D demonstrate encouraging safety and efficacy in B-cell non-Hodgkin lymphoma SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- ...

Carvykti has boxed warnings for risk of certain immune system problems, nervous system problems, and other blood cancers. Serious side effects of the drug tend to be rare. This drug can also cause ...